This study is looking at the safety and efficacy of the drug combination of ASP8374 with
cemiplimab in people with recurrent malignant glioma.
The study will be conducted in two parts, the first portion of the study will be to establish
the highest dose of ASP8374 that can be given safely with cemiplimab and will be used as the
recommended dose of ASP8374 in combination with cemiplimab for the second portion of the
study. The second portion of the study will be to compare the effect of having ASP8374 in
combination with cemiplimab prior to surgery.
The names of the study drugs involved in this study are:
- ASP8374
- Cemiplimab
- 89Zr-Df-IAB22M2C (Administered as part of scan procedure)
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Astellas Pharma Inc ImaginAb, Inc. Regeneron Pharmaceuticals